Skip to content
← Go back
| Paper 1 | |
|---|
| Patient Name | Fawziyah Hussein Ismail |
|---|
| Age | 77 |
|---|
| Clinical evaluation | |
|---|
| Consultation date | 09/09/2024 |
|---|
| Previous assessment for TAVI | no |
|---|
| History and risk factors | |
|---|
| Prior CABG | no |
|---|
| Prior aortic valve procedure | no |
|---|
| Prior other valve procedure | no |
|---|
| Number of previous cardiac surgery | none |
|---|
| Prior arrhythmia | no |
|---|
| Permanent peacemaker | no |
|---|
| Other history | |
|---|
| Previous CVA or TIA | no |
|---|
| Extracardiac arteriopathy | no |
|---|
| Hypertension | yes |
|---|
| Diabetes melitus | yes |
|---|
| Renal insufficiency requiring dialysis | no |
|---|
| Renal insufficiency requiring renal transplant | no |
|---|
| Chronic lung disease | no |
|---|
| Malignancy (prior or current) | no |
|---|
| Paper 2 | |
|---|
| Clinical evaluation continued | |
|---|
| Syncope | no |
|---|
| CCS | yes |
|---|
| NYHA | I |
|---|
| Clinical data | |
|---|
| Height (cm) | 165 |
|---|
| Weight (kg) | 80 |
|---|
| Body mass index (BMI) | 31.7 |
|---|
| Hemoglobin (g/dl) | 12.5 |
|---|
| Creatinine (mg/dl) | 1.1 |
|---|
| Creatinine clearance | 72 |
|---|
| Pre-operative special investigations | |
|---|
| ECG | |
|---|
| Rhythm | Regular |
|---|
| PR Interval (ms) | 130 |
|---|
| QRS Duration (ms) | 85 |
|---|
| ECHO (TTE or TOE) | |
|---|
| Mean gradient across aortic valve (mm Hg) | 40 |
|---|
| Aortic valve area (cm2) | 0.8 |
|---|
| Ejection fraction (%) | 74 |
|---|
| Associated valvular lesions | |
|---|
| Aortic insufficiency | none |
|---|
| Mitral insufficiency | mild |
|---|
| Mitral stenosis | none |
|---|
| Tricuspid insufficiency | none |
|---|
| Tricuspid stenosis | none |
|---|
| Pulmonary insufficiency | none |
|---|
| Pulmonary stenosis | none |
|---|
| Paper 3 | |
|---|
| TAVI evaluation | |
|---|
| Risk profile | |
|---|
| Predicted operative risk | Low |
|---|
| STS score (%) | 1.36 |
|---|
| Euroscore II (%) | 0.9 |
|---|
| Contra-indication to surgery | no |
|---|
| Reason for contra-indication to surgery | |
|---|
| Frailty | no |
|---|
| Porcelain aorta | no |
|---|
| Patent LIMA graft | no |
|---|
| Hostile thorax | no |
|---|
| Further investigations | |
|---|
| Lung function tests | no |
|---|
| Angiogram | yes |
|---|
| Number of diseased vessels | 2 |
|---|
| PCI or revascularization indicated | yes |
|---|
| CT coronary angiogram | yes |
|---|
| Pre TAVI CT Assessment | |
|---|
| Aortic Annulus | |
|---|
| Perimeter (mm) | 71.3 |
|---|
| Perimeter derived (mm) | 22.7 |
|---|
| AREA (mm2) | 403.8 |
|---|
| Area derived (mm) | 22.1 |
|---|
| LVOT | |
|---|
| Perimeter (mm) | 69.3 |
|---|
| Perimeter derived (mm) | 22.8 |
|---|
| AREA (mm2) | 356.4 |
|---|
| Area derived (mm) | 21.5 |
|---|
| Sinus of Valsalva | |
|---|
| Left | 30.4 |
|---|
| Right | 27.3 |
|---|
| Non | 27 |
|---|
| MAX Ascending Aorta Angle | 31.2 |
|---|
| STJ Angle | 25.3 |
|---|
| Measurements | |
|---|
| Aortic Annulus | |
|---|
| Min Aortic Annulus Diameter (mm) | 20.3 |
|---|
| Max Aortic Annulus Diameter (mm) | 25.7 |
|---|
| Average Aortic Annulus Diameter | 23.4 |
|---|
| LVOT | |
|---|
| Min LVOT diameter | 16.4 |
|---|
| Max LVOT diameter | 26.1 |
|---|
| Average Aortic Annulus Diameter | 21.7 |
|---|
| STJ angle | |
|---|
| Min | 25.3 |
|---|
| Max | 26.4 |
|---|
| Average | 25.7 |
|---|
| LCA Height | 11.3 |
|---|
| RCA Height | 16.4 |
|---|
| Aortic Valve Calcification | Moderate |
|---|
| Aortic Root Angulation | 39 |
|---|
| Paper 4 | |
|---|
| TAVI procedure | |
|---|
| Procedure date | 09/10/2024 |
|---|
| Type of anesthesia | local |
|---|
| TOE used intra-operatively | no |
|---|
| Valve in valve procedure | no |
|---|
| Procedural success | yes |
|---|
| Procedural complications (VARC < 72 hours) | |
|---|
| Intra-procedural mortality | no |
|---|
| Consequent mortality < 72 hr post-procedure | no |
|---|
| Myocardial infarction | no |
|---|
| Stroke or TIA | no |
|---|
| New PML | no |
|---|
| Bleeding complications | no |
|---|
| Vascular complication | no |
|---|
| Valve dysfunction | no |
|---|
| Other thrombotic or embolic complications | no |
|---|
| Cardiopulmonary bypass required | no |
|---|
| Other procedural complications | no |
|---|
| Conversion to open heart surgery | no |
|---|
| Device information | |
|---|
| Number of valves implanted | 1 |
|---|
| Valve 1 | |
|---|
| Type implanted | Boston |
|---|
| Medtronic data | |
|---|
| Boston data | |
|---|
| Model implanted | ACURATE neo2 |
|---|
| Size implanted | M |
|---|
| Valve result | not-detectable |
|---|
| Hospital stay | |
|---|
| Days in ICU | 1 |
|---|
| Days in ward | 1 |
|---|
| Paper 5 | |
|---|
| Follow up information | |
|---|
| General follow up | |
|---|
| Stroke / TIA since TAVI | no |
|---|
| PPM since TAVI | no |
|---|
| Hospital admission | no |
|---|
| Follow up 30 days | |
|---|
| Stroke / TIA since TAVI | no |
|---|
| PPM since TAVI | no |
|---|